Built By BioGenerator, Panome Bio Launches with $6M Series A
Summary
ST. LOUIS, March 15, 2023 /PRNewswire/ -- Panome Bio, a metabolomics and proteomics services company that provides biopharma innovators unparalleled access into the biomolecules closest to phenotype and function, announced the closing of a growth financing round led by Telegraph Hill Partners, a life science venture capital and growth equity firm based in San Francisco, CA. Panome Bio works with pharmaceutical and biotech companies and pairs Next-Generation Metabolomics with high-throughput proteomics to further advance research in biomarker discovery and drug development.Dr. "The financing will be used to develop new technologies and capabilities, expand laboratory facilities, and grow the Panome Bio team to service the increasing interest in metabolomics and proteomics data. Deval Lashkari, Rob Capone, and Alex Herzick from Telegraph Hill Partners will join Panome Bios board of directors. For more information, please visit www.panomebio.com, follow us on LinkedIn at www.linkedin.com/company/panome-bio, or email at info@panomebio.com.Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in commercial stage life science, medical technology, and healthcare companies.